Navigation Links
Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
Date:10/9/2008

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine's annual survey of Top Employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. With a 2008 ranking of eighth, the Company is in the top ten for the first time, moving up from a 2007 ranking of 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"This top ten ranking underscores Millennium's commitment not only to breakthrough science, but also to its employees and overall working environment," said Stephen Gansler, Senior Vice President, Human Resources, Millennium. "It is now more important than ever for us to keep up this positive work culture as we recruit for the hundreds of new additions over the next few months."

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and a research-driven environment. The 2008 survey sought to identify the companies with the best reputations as employers, based on nearly 4,000 survey responses from readers of Science and other respondents in industry. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry. For the complete business office feature with individual company rankings, please visit: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articl es/ 2008_10_10/science.opms.r0800061.

Millennium was acquired by Takeda Pharmaceutical Company Limited in May, 2008.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, http://www.millennium.com.

Editor's Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com

Media Contact:

Manisha Pai

(617)551-7877

manisha.pai@mpi.com


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
2. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
3. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
6. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
7. Millennium Announces $200,000 Purchase Order From Greek Distributor
8. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
10. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
11. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces ... at the Company,s Annual and Special Meeting. ... place on Thursday, December 15, 2016 at Mount ... EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta ... meeting and management information circular, containing the matters to be ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
Breaking Biology News(10 mins):